introduction monoclonal antibody rituximab NUMBER years ago led marked improvement treatment lymphoma nhl patients experience complete response therapy respond relapse way improving efficacy monoclonal antibodies use deliver cytotoxic agents radionuclides tumor monoclonal antibodies armed radionuclides provide means targeting radiation therapy specifically tumor cells express antigen antibody originally raised subsequently NUMBER radiolabeled monoclonal antibody tiuxetan approved treatment patients relapsed refractory follicular transformed nhl including patients follicular lymphoma refractory rituximab attempts optimize efficacy radioimmunotherapy ongoing factors need considered choice choice delivery used choice radionuclide cd25 alpha ideal choice target antigen number tumor cells including adult leukemia atl NUMBER NUMBER patients atl responded treatment targets receptoralpha alpha conjugated 90y dose radionuclide delivered tumor increased dramatically using process antibody radioactivity delivered separately antigen order improve tissue ratios commonly used radionuclides radioimmunotherapy date pretargeting process makes use feasible results experiments involving pretargeting process radionuclides leukemia lymphoma models suggest alphaemitters effective treatment small tumors micrometastases isolated cells suitable use large tumor masses lymphomas references NUMBER non hodgkins 90y ibritumomab low grade b cell il 2r expressed t cell anti tac interleukin NUMBER il 2r step tumor normal beta emitters short lived alpha beta emitting alpha emitters beta emitters antibody antigen